New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 22, 2014
10:58 EDTIP, AMGN, NOV, GE, JPM, ETNAmgen, Eaton, GE, three others could see good growth, Barron's says
Amgen (AMGN), Eaton (ETN), General Electric (GE), International Pepper (IP), JPMorgan Chase (JPM), and National Oilwell Varco (NOV) are all dividend stocks with growth potential in both payouts and profits, Barron's contends in a feature article. Reference Link
News For AMGN;ETN;GE;IP;JPM;NOV From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
July 24, 2015
12:44 EDTAMGNAmgen announces FDA approval of expanded Kyprolis indication
Subscribe for More Information
12:27 EDTAMGNFDA approves expanded use of Kyprolis in multiple myeloma patients
The FDA announced that on July 24 the administration approved carfilzomib, or Kyprolis, marketed by Onyx Pharmaceuticals, an Amgen (AMGN) subsidiary, in combination with lenalidomide and dexamethasone for the treatment of patients with relapsed multiple myeloma who have received one to three prior lines of therapy. The revised labeling includes new Warnings and Precautions for VTE, cardiac toxicities, acute renal failure, pulmonary toxicities, and hypertension. The increased safety risks, including mortality, for elderly patients is described. Detailed safety information in the prescribing information was also updated for use of carfilzomib monotherapy. Reference Link
July 23, 2015
11:57 EDTIPOptions with increasing put volume
Subscribe for More Information
09:10 EDTAMGNAmgen submits NDA for Kyprolis in relapsed multiple myeloma
Amgen submitted a supplemental New Drug Application to the FDA for Kyprolis for Injection to seek an expanded indication for the treatment of patients with a form of blood cancer, relapsed multiple myeloma, who have received at least one prior therapy. Kyprolis currently has accelerated approval in the U.S. for the treatment of patients with relapsed multiple myeloma as a monotherapy. The sNDA is based on data from the global Phase 3 ENDEAVOR trial in which relapsed multiple myeloma patients treated with Kyprolis and dexamethasone lived twice as long without their disease worsening, demonstrating statistically and clinically significant superiority over Velcade.
08:11 EDTGEGE's CDF unit extends inveotry finance program with Husqvarna Group
Subscribe for More Information
07:16 EDTJPMChase Card Services, Southwest announce extension to co-branded card agreement
Subscribe for More Information
07:13 EDTJPMJPMorgan management to meet with Deutsche Bank
Subscribe for More Information
July 22, 2015
07:23 EDTGEFrench minister 'reassured' by elements of Alstom, GE deal talks, Reuters says
Subscribe for More Information
06:09 EDTJPM4 arrested men suspected of JPMorgan hacking, NYT reports
Subscribe for More Information
July 21, 2015
19:23 EDTJPMJPMorgan Chase to expand into Washington D.C., NY Post says
Subscribe for More Information
16:13 EDTJPMJPMorgan releases results of 2015 Dodd-Frank Stress Test
Common Equity Tier 1 ratio would be 8.1% in severe adverse scenario and Tier 1 risk-based capital ratio would be 9.6%. Reference Link
12:47 EDTAMGNPiper confident in Regeneron approval by Friday
After Amgen's (AMGN) Repatha received marketing authorization in Europe, making it the first of the anti-PCSK9 antibody to be approved worldwide, Piper Jaffray analyst Edward Tenthoff expressed confidence that Regeneron (REGN) and Sanofi's (SNY) anti-PCSK9 antibody Praluent will be approved by Friday's FDA action date. Tenthoff believes Praluent will eventually be a blockbuster drug, but anticipates the launch to be slow. He keeps a Neutral rating on Regeneron with a $484 price target.
11:49 EDTAMGNNovartis may sell Amgen's cancer drug as soon as September, Bloomberg says
Subscribe for More Information
08:35 EDTJPMVarian Medical signs agreement to operate first proton facility in New York
Varian Medical Systems (VAR) announced that it has entered into an agreement with New York Proton Management, a consortium of leading New York healthcare institutions including Memorial Sloan Kettering Cancer Center, Mount Sinai Health System, Montefiore Health System, and ProHEALTH Medical Management formed to operate The New York Proton Center, the first proton facility in New York State. Varian will provide the center, which will have four treatment rooms and a research room, with its ProBeam system, as well as 10 years of service for approximately $115M. The center, which will be located in Manhattan, is expected to open for treatment in the first half of 2018. Varian expects to book the equipment portion of the order in Q4 with the remainder of the order to be booked in accordance with the company's policies over the term of the agreement. Under an agreement with MM Proton I, LLC, the project developer, Varian's international subsidiary in Switzerland will provide $91.5M in project financing, including a six-and-half-year $73M senior first lien loan at 9% interest and a six-and-half-year $18.5M subordinate loan at up to 13.5% interest. Other lenders for the $242.7M in total project loans include JPMorgan Chase Bank (JPM) and an affiliate of The Goldman Sachs Group (GS). The project facility is managed by Murphy & McManus, a Boston-based developer of healthcare and life science facilities and Norton Travis of NLT Advisors served as project coordinator on behalf of the consortium.
07:12 EDTAMGNAmgen's Repatha granted marketing authorization by EC
Amgen announced that the European Commission, or EC, has granted marketing authorization for Repatha, or evolocumab, the first proprotein convertase subtilisin/kexin type 9, or PCSK9, inhibitor to be approved in the world, for the treatment of patients with uncontrolled cholesterol who require additional intensive low-density lipoprotein cholesterol reduction. Repatha is a human monoclonal antibody that inhibits PCSK9, a protein that reduces the liver's ability to remove LDL-C, or "bad" cholesterol, from the blood.
July 20, 2015
16:20 EDTGEFederal Reserve establishes enhanced standards for GE Capital
Subscribe for More Information
13:03 EDTJPMFed proposes final rule on capital surcharges for largest U.S. banks
Subscribe for More Information
09:04 EDTGEGE chooses Microsoft Office 365 fro employee collaboration and productivity
Subscribe for More Information
07:16 EDTJPMJPMorgan boosts Spanish bond holdings amid Greek deal, Bloomberg says
Subscribe for More Information
06:16 EDTGEAlstom sees General Electric deal completed in coming months, Reuters reports
Alstom (ALSMY) expects to complete the transaction with GE (GE) in the coming months, Reuters reports. Reference Link
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use